tiprankstipranks
KalVista Pharmaceuticals (DE:4XC1)
FRANKFURT:4XC1
Germany Market
4XC1
KalVista Pharmaceuticals
RESEARCH TOOLSreports

KalVista Pharmaceuticals (4XC1) Stock News & Sentiment

0 Followers
Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
Premium
Ratings
Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
3d ago
KALV
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
Premium
Ratings
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
14d ago
KALV
Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
Premium
Ratings
Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
29d ago
KALV
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
Premium
Company Announcements
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV
3M ago
KALV
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
Premium
Ratings
Strong Ekterly Launch and Latin America Expansion Underscore Buy Rating on KalVista
3M ago
KALV
KalVista Highlights Strong EKTERLY Launch and Global Uptake
Premium
Company Announcements
KalVista Highlights Strong EKTERLY Launch and Global Uptake
3M ago
8K
KALV
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
Premium
Ratings
KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating
3M ago
KALV
More DE:4XC1 News >

4XC1 News on the Web

Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
TipRanks News
Neutral
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
TipRanks News
Neutral
KalVista Pharmaceuticals (KALV) Gets a Buy from Stifel Nicolaus
TipRanks News
Bearish
Major KalVista Stakeholder Makes Eye-Catching Move With Fresh Stock Sale
TipRanks News
Neutral
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS)
TipRanks News
Bullish
KalVista price target lowered to $28 from $29 at Citizens
TipRanks News
Bullish
KalVista price target raised to $42 from $39 at Stifel
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
DE:4XC1
Sector Average
Media Buzz
This Week1 articles
Weekly Average3.75 articles
News Sentiment
This Week50%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:4XC1’s Media Buzz Sentiment?
1 articles about DE:4XC1 were published this week. In an average week, 3.75 articles are published.
    What is DE:4XC1’s weekly average amount of articles?
    In an average week, 3.75 articles about DE:4XC1 are published.
      What is DE:4XC1’s News Sentiment?
      50% of articles about DE:4XC1 were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        NBIXNeurocrine
        STAAStaar Surgical
        AORTArtivion
        OWLTOwlet
        HUMHumana
        Showing the stocks with the most bullish news sentiment over the past week